Correspondence 0001193125-24-004489 from Chemours Co (CC) (CIK 0001627223) (CC)
Chemours Co (CC) (CIK 0001627223)
Date: Jan. 8, 2024 · CIK: 0001627223 · Accession: 0001193125-24-004489
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-36794
Referenced dates: January 3, 2024
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services Form 10-K for Fiscal Year Ended December 31, 2022 Form 8-K filed February 9, 2023 Response Dated December 22, 2023 File No. 001-36794
Re: Chemours Co
Dear Sir or Madam:
On behalf of The Chemours Company (the “Company” or “Chemours”), this letter responds to the comment of the Staff of the Division of Corporation Finance (the “Staff”) of the U.S. Securities and Exchange Commission (the “SEC” or the “Commission”) contained in the letter dated January 3, 2024 (the “Comment Letter”) relating to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed on February 10, 2023 (the “2022 Form 10-K”) and the Company’s Current Report on Form 8-K furnished on February 9, 2023 (the “Form 8-K”). Capitalized terms used and otherwise not defined have the meanings assigned to such terms in the 2022 Form 10-K, the Form 8-K or their exhibits, as applicable.
The headings and numbered paragraph of this letter correspond to the headings and paragraph number contained in the Comment Letter, and to facilitate your review, we have reproduced the text of the Staff’s comment in boldfaced print below, followed by the Company’s response to the comment.
Form 8-K Filed February 9, 2023
Exhibit 99.1
1. We note your response to prior comment 2 regarding your presentation of adjusted EBITDA margin only at the segment level as your segment profit measure. However, we note within the Segment Financial and Operating Data section of your earnings press releases that you include the presentation of adjusted EBITDA margin at the consolidated level. As such, we continue to request that you present the most directly comparable financial measure or measures calculated and presented in accordance with US GAAP in accordance with Item 10(e)(1)(i)(A) of S-K.
Response: We acknowledge the Staff’s comment and respectfully advise the Staff that, in future reports, we will remove the presentation of Adjusted EBITDA margin at the consolidated level in our earnings releases that will be furnished with a Current Report on Form 8-K.
Division of Corporate Finance
January 8, 2024
Page Two
* * *
If you require additional information or have any questions about this letter, please do not hesitate to contact me at jonathan.lock@chemours.com or (302) 773-1000 or our Chief Accounting Officer, Camela T. Wisel, at camela.t.wisel@chemours.com or (302) 773-3234.
Sincerely,
/s/ Jonathan Lock
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
January 8, 2024
VIA EDGAR
United States Securities and Exchange
Commission
Division of Corporation Finance
Office of
Industrial Applications and Services
100 F Street N.E.
Washington, D.C. 20549-7010
Re:
Chemours Co
Form 10-K for Fiscal Year Ended December 31, 2022
Form 8-K filed February 9, 2023
Response Dated December 22, 2023
File No. 001-36794
Dear Sir or Madam:
On behalf of The Chemours Company (the
“Company” or “Chemours”), this letter responds to the comment of the Staff of the Division of Corporation Finance (the “Staff”) of the U.S. Securities and Exchange Commission (the “SEC” or the
“Commission”) contained in the letter dated January 3, 2024 (the “Comment Letter”) relating to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31,
2022 filed on February 10, 2023 (the “2022 Form 10-K”) and the Company’s Current Report on Form 8-K furnished on February 9, 2023 (the
“Form 8-K”). Capitalized terms used and otherwise not defined have the meanings assigned to such terms in the 2022 Form 10-K, the Form 8-K or their exhibits, as applicable.
The headings and numbered paragraph of this letter correspond to the headings and
paragraph number contained in the Comment Letter, and to facilitate your review, we have reproduced the text of the Staff’s comment in boldfaced print below, followed by the Company’s response to the comment.
Form 8-K Filed February 9, 2023
Exhibit 99.1
1.
We note your response to prior comment 2 regarding your presentation of adjusted EBITDA margin only at the
segment level as your segment profit measure. However, we note within the Segment Financial and Operating Data section of your earnings press releases that you include the presentation of adjusted EBITDA margin at the consolidated level. As such, we
continue to request that you present the most directly comparable financial measure or measures calculated and presented in accordance with US GAAP in accordance with Item 10(e)(1)(i)(A) of S-K.
Response: We acknowledge the Staff’s comment and respectfully advise the Staff that, in future reports, we will remove the
presentation of Adjusted EBITDA margin at the consolidated level in our earnings releases that will be furnished with a Current Report on Form 8-K.
Division of Corporate Finance
January 8, 2024
Page Two
* *
*
If you require additional information or have any questions about this letter, please do not
hesitate to contact me at jonathan.lock@chemours.com or (302) 773-1000 or our Chief Accounting Officer, Camela T. Wisel, at camela.t.wisel@chemours.com or (302)
773-3234.
Sincerely,
/s/ Jonathan Lock
Jonathan Lock
Senior Vice President
Chief Financial Officer
cc:
Kristine M. Wellman, Senior Vice President, General Counsel & Corporate
Secretary, The Chemours Company
Scott Lesmes, Partner, Morrison & Foerster LLP